During the 1990s and early 2000s generic competition drove down the prices of ARVs. Without these massive price reductions, nearly a million additional people would be dead or dying now in South Africa. In 2005 many generic producing countries, including India, became TRIPS compliant. This means that medicines developed since 1995 cannot as easily be produced by generic companies operating in India.
Pressure is being applied by the European Union on the Indian government to sign a bilateral trade agreement that will further stifle competition on essential medicines still under...Read more